A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa
Latest Information Update: 29 Aug 2022
Price :
$35 *
At a glance
- Drugs Alglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi Genzyme
- 15 Mar 2022 New trial record